Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$12.82M, compared with $570K a year earlier. Trailing-twelve-month net income was -$39.95M. Over 3 fiscal years it compounded at +13.7% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$17.43M (-34.4%) for the fiscal year ending Dec 2026, a slowdown from the -27.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$12.82M-12.6% QoQ
- Last fiscal yearDec 2025
- -$26.56M-27.7% YoY
- LTMMar 2026
- -$39.95M+162.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2349.6% | +106.5% | +2456.2 pp |
| 1 year | -27.7% | -34.4% | -6.7 pp |
| 3-year CAGR | +13.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (26.56M) USD
- Year-over-year change
- +27.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (26.56M) | +27.7% |
| FY2024 | 2024-12-31 | (36.73M) | -20.2% |
| FY2023 | 2023-12-31 | (30.54M) | -69.1% |
| FY2022 | 2022-12-31 | (18.06M) | -80.3% |
| FY2021 | 2021-12-31 | (10.02M) | — |
Net Income vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +162.9% is the 2nd highest of 10, against a peer median of -7.7%.
- Over three fiscal years its annual growth of +13.7% compares with a peer median of +2.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $104.29M USD | +8.2% | -6.9% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $103.27M USD | -65.4% | +96.0% | 2409.4% |
| LTM Mar 2026 | $86.3M USD | +66.7% | — | 2193.7% | |
| LTM Mar 2026 | $78.34M USD | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M USD | -7.7% | +35.7% | — |
| LTM Mar 2026 | $58.88M USD | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $44.95M USD | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $39.95M USD | +162.9% | +13.7% | — | |
| LTM Mar 2026 | $37.1M USD | +163.8% | — | 14.5% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$12.18M CAD | -73.6% | +21.9% | 66.4% |
| Peer median (excluding UNCY) | — | -7.7% | +2.0% | 1130.0% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 966K | 1.05M | 1.77M | 2.35M | 2.64M |
| Change in Working Capital | (105K) | 1.18M | (93K) | (427K) | (5.95M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.24M | 1.27M | 1.28M | 790K | (2.51M) |
| Other Working Capital | (1.35M) | (89K) | (1.37M) | (1.22M) | (3.45M) |
| Other Non-Cash Items | 3.38M | 21K | 10.3M | 5.8M | (2.02M) |
| Operating Cash Flow | (5.77M) | (15.65M) | (18.28M) | (28.58M) | (31.32M) |
| Capital Expenditures | (29K) | (2K) | (12K) | (72K) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (12.07M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (29K) | (2K) | (12K) | (72K) | (12.1M) |
| Debt Repayment | (15K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 22.27M | 11K | 0 | 683K | 48.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.1M) | 0 |
| Other Financing Activities | 119K | (482K) | (2.65M) | (4.5M) | (1.61M) |
| Financing Cash Flow | 22.38M | (471K) | 27.54M | 45.09M | 46.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.58M | (16.12M) | 9.25M | 16.44M | 3.06M |
| Free Cash Flow | (5.8M) | (15.65M) | (18.3M) | (28.65M) | (31.34M) |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.